Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.

British journal of clinical pharmacology - 1 Apr 2014

Verhoef Talitha I, Redekop William K, Daly Ann K, van Schie Rianne M F, de Boer Anthonius, Maitland-van der Zee Anke-Hilse

Abstract excerpt

Coumarin derivatives, such as warfarin, acenocoumarol and phenprocoumon are frequently prescribed oral anticoagulants to treat and prevent thromboembolism. Because there is a large inter-individual and intra-individual variability in dose-response and a small therapeutic window, treatment with coumarin derivatives is challenging. Certain polymorphisms in CYP2C9 and VKORC1 are associated with lower dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Cost-Benefit Analysis

Share to Cytochrome P-450 CYP2C9

Share to Drug Dosage Calculations

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 23919835
DOI: 10.1111/bcp.12220
PMCID: PMC3971980

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.PMID 23919835Read ↗

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?Semantic proximity Read ↗

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.Semantic proximity Read ↗

Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumonSemantic proximity Read ↗

The future prospects of pharmacogenetics in oral anticoagulation therapySemantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

Genotype-guided coumarin dosing: where are we now and where do we need to go next?Semantic proximity Read ↗

Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.Semantic proximity Read ↗

Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.Semantic proximity Read ↗

Pharmacogenomics of 4-hydroxycoumarin anticoagulants.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.Semantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.